The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluating the combined role of HHLA2 and PD-L1 as biomarkers in first-line nivolumab therapy in advanced clear cell renal cell carcinoma.
 
Yasmin Nabil Laimon
No Relationships to Disclose
 
Nourhan El Ahmar
No Relationships to Disclose
 
Opeyemi Jegede
No Relationships to Disclose
 
Aseman Baghari Sheshdeh
No Relationships to Disclose
 
Gordon Freeman
Stock and Other Ownership Interests - Bioentre; Geode Therapeutics; GV20 Oncotherapy; IgM Biosciences; Invaria; ITeos Therapeutics; Nextpoint; Triursus Therapeutics; Xios Therapeutics
Consulting or Advisory Role - Alixia (I); Amgen (I); Bicara Therapeutics (I); Bioentre; Bioentre (I); Corner Therapeutics (I); Elpiscience (I); Fibrogen (I); Geode Therapeutics; GlaxoSmithKline (I); GV20 Oncotherapy; IgM Biosciences; Iome (I); Iome Bio; ITeos Therapeutics; Janssen (I); Monopteros Therapeutics (I); Nextpoint; Santa Ana Bio; Selecta Biosciences (I); Simcere of America; SQZ Biotech (I); Surface Oncology (I)
Research Funding - Abbvie (I); Bristol-Myers Squibb; Calico (I); Erasca, Inc (I); Ipsen (I); Merck Sharp & Dohme (I); Moderna Therapeutics (I); Novartis (I); Quark (I); Roche/Genentech (I); Taiwan Bio (I); UCB (I); Vertex (I)
Patents, Royalties, Other Intellectual Property - Amplimmune/Astrazeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Dako; EMD Serono; Leica Biosystems; Mayo Clinic; Merck; Novartis; Novartis (I); Pfizer (I); Pfizer (I); Roche/Genentech; Roche/Genentech (I)
 
David McDermott
Consulting or Advisory Role - alkermes; Arcus Biosciences; Bristol-Myers Squibb; Cullinan Oncology; Eisai; EMD Serono; exelixis; Iovance Biotherapeutics; Lilly; Merck; Pfizer; Synthekine; Werewolf Therapeutics; Xilio Therapeutics
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
 
Michael Atkins
Leadership - Werewolf Therapeutics
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma
Consulting or Advisory Role - 23AndMe; Abbvie; Agenus; AstraZeneca; Aveo; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Innovent Biologics; IO Biotech; Jazz Pharmaceuticals; Merck; Novartis; Oncorena; Pfizer; Pliant; Pyxis; Replimune; Sanofi; Simcha Therapeutics; Syncona; Werewolf Pharma
Research Funding - Agenus (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - BMS Canada; BMS Sweden
 
Sabina Signoretti
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; crispr therapeutics; Merck
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Receives royalties from Biogenex
Other Relationship - AACR; NCI
 
Kathleen Mahoney
Consulting or Advisory Role - Jefferies
Research Funding - Bristol-Myers Squibb; NextPoint Therapeutics